A Long-term Study of HSK44459 Tablets in Participants With Bechet's Disease

This is a long-term extension study of HSK44459-202 in eligible participants who have completed the Week 12 visit of the originating Study HSK44459-202. The total duration of this study will be up to 56 weeks which will include a 52-week treatment period, and a 4-week safety follow-up period after the last study intervention administration. Safety will be assessed by the incidence and severity of adverse events during the study.

NCT Number	NCT07070739
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	Bechet's Disease
Enrollment	120 participants
Start Date	2025-07
Primary Completion	2027-07 (estimated)
Study Completion	2027-07 (estimated)
Updated on ClinicalTrials.gov	2025-07-17